MiNK Therapeutics, Inc. INKT
9.53 USD -0.69 (-6.79%)
At closeNov 12, 2026, 4:00 PM EST
9.53 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
9.53 Day range 10.37
8.48 52-week range 16.93
- YTD
- -14.53%
- 1 year
- -30.34%
News
seekingalpha.com MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call Transcript
zacks.com MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates MiNK Therapeutics, Inc. (INKT) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.65 per share a year ago.
marketbeat.com What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call MiNK Therapeutics NASDAQ: INKT has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with…
benzinga.com MiNK Therapeutics Q3 2026 Earnings Call Transcript MiNK Therapeutics (NASDAQ:INKT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com MiNK Therapeutics Q3 EPS $(0.50) Beats $(0.66) Estimate MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.66) by 24.24 percent. This is a 23.08 percent increase over losses of…
globenewswire.com MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering unmodified, off-the-shelf allogeneic invariant natural killer…- benzinga.com MiNK Therapeutics Presents Preclinical Cancer Data For iNKT Cell Therapy Platform At SITC 2026 Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing,…
globenewswire.com MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies,…
benzinga.com HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38 HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.
benzinga.com MiNK Therapeutics To Hold Webcast On Nov. 11 To Review Financial Results, Offer Update On Its Clinical Development Of AgenT-797 MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today…
globenewswire.com MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the…
benzinga.com B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50 B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
globenewswire.com MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell…
globenewswire.com MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature
seekingalpha.com MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
marketbeat.com MiNK Therapeutics Q2 Earnings Call Highlights MiNK Therapeutics NASDAQ: INKT said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and…
benzinga.com MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…- benzinga.com MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 41.51 percent increase over losses of…
globenewswire.com MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT)…
globenewswire.com MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies…
zacks.com Here's Why You Should Add INKT Stock to Your Portfolio Now MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
globenewswire.com MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)…
globenewswire.com MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for…
globenewswire.com MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell…
seekingalpha.com MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
marketbeat.com MiNK Therapeutics Q1 Earnings Call Highlights MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
globenewswire.com MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase…
benzinga.com Earnings Scheduled For May 15, 2026 
globenewswire.com MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness NEW YORK and LVIV, Ukraine, May 14, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and…- benzinga.com Earnings Scheduled For March 31, 2026
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Domo Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket Domo Inc (DOMO) stock jumped 48.8% in pre-market trading after beating Q4 earnings expectations by 117.65% and reporting a rise in revenue.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For November 14, 2025
- benzinga.com Earnings Scheduled For August 14, 2025
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session